Department of Nephrology, Odense University Hospital, Odense, Denmark, and Cardiovascular and Renal Research, Institute of Molecular Medicine, Clinical Institute, University of Southern Denmark, Odense, Denmark.
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Transplantation, Néphrologie et Immunologie Clinique, Lyon, France.
Front Immunol. 2022 Jul 25;13:945288. doi: 10.3389/fimmu.2022.945288. eCollection 2022.
Better characterization of the potential kidney transplant recipient using novel biomarkers, for example, pretransplant plasma endotrophin, will lead to improved outcome after transplantation. This mini-review will focus on current knowledge about pretransplant recipients' characteristics, biomarkers, and immunology. Clinical characteristics of recipients including age, obesity, blood pressure, comorbidities, and estimated survival scores have been introduced for prediction of recipient and allograft survival. The pretransplant immunologic risk assessment include histocompatibility leukocyte antigens (HLAs), anti-HLA donor-specific antibodies, HLA-DQ mismatch, and non-HLA antibodies. Recently, there has been the hope that pretransplant determination of markers can further improve the prediction of posttransplant complications, both short-term and long-term outcomes including rejections, allograft loss, and mortality. Higher pretransplant plasma endotrophin levels were independently associated with posttransplant acute allograft injury in three prospective European cohorts. Elevated numbers of non-synonymous single-nucleotide polymorphism mismatch have been associated with increased allograft loss in a multivariable analysis. It is concluded that there is a need for integration of clinical characteristics and novel molecular and immunological markers to improve future transplant medicine to reach better diagnostic decisions tailored to the individual patient.
更好地描述潜在的肾移植受者,例如,使用新型生物标志物(如移植前血浆内毒素),将导致移植后结果得到改善。这篇迷你综述将重点介绍目前关于移植前受者特征、生物标志物和免疫学的知识。受者的临床特征,包括年龄、肥胖、血压、合并症和估计的生存评分,已被用于预测受者和移植物的生存。移植前免疫风险评估包括组织相容性白细胞抗原(HLA)、抗 HLA 供体特异性抗体、HLA-DQ 错配和非 HLA 抗体。最近,人们希望移植前确定标志物可以进一步改善对移植后并发症的预测,包括短期和长期结果,包括排斥反应、移植物丢失和死亡率。在三个前瞻性欧洲队列中,较高的移植前血浆内毒素水平与移植后急性移植物损伤独立相关。在多变量分析中,非同义单核苷酸多态性错配数量的增加与移植物丢失增加相关。结论是,需要整合临床特征和新型分子及免疫学标志物,以改善未来的移植医学,从而做出更好的诊断决策,针对每个患者进行个体化治疗。